A girl is entertained by clowns as she waits after receiving a dose of the Soberana 02 vaccine in Havana, Cuba, August 2021. Photo: AP / Ramon Espinosa.
Until the end of October 22, 10,708,842 people have received at least one dose of one of the Cuban Sovereign 02 anticovid vaccines, Sovereign Plus and Abdala, and of them 9,434,575 have already received the second dose and 9,137,029, the third . To date, 9,996,978 have a complete vaccination program, 90.2% of the Cuban populationthe Ministry of Public Health reported.
In an update note, Minsap clarified that single dose Soberana Plus vaccinates are included in the first dose.
Currently, 8,619,483 people have booster doses (325,318 in the clinical study and 8,294,165 in the booster vaccination). applied to the population of selected areas and risk groups).
mass vaccination
The Center for the State Control of Medicines, Equipment and Medical Devices (Cecmed) granted on 9 July 2021 the emergency use authorization (AUE) to the Abdala 50 µg vaccine, whose holder is the Center for Genetic Engineering and Biotechnology (CIGB), in compliance and in compliance with the provisions of the regulations and provisions in force, once the compliance with the requisites and parameters required in terms of quality, safety and efficacy has been ascertained.
On 20 August 2021, Cecmed granted the AUE to the Soberana 02 and Soberana Plus vaccines, the owner of which is the Finlay Vaccine Institute (IFV).
Mass vaccination began on July 29, 2021, in the population over the age of 19 in epidemiological risk areas and risk groups at the level of all provinces. In addition, in the pediatric population aged two to 18 years across the country.
The total number of doses administered during mass vaccination is 31,609,869.
Clinical study
Following the approval of the booster dose strategy, the clinical study with candidate vaccines (Soberana 01 and Mambisa) and the initiation of vaccination with a fourth dose, starting with healthcare professionals and risk groups, were approved.
These booster doses add to the number of doses applied in the country in its accumulation, MINSAP specified.
The study began in November 2021, with health workers, the population of the selected territories and other groups at risk. In the clinical study 325,318 doses were administered.
health intervention
Since the beginning of May 2021, the Minister of Public Health, supported by Article 64 of Law 41, Public Health Law, of 13 July 1983, has approved a health intervention with Cuban candidates for the Abdala and Soberana 02 vaccine in groups and territories at risk.
The trial began that same month and included health workers, BioCubaFarma, medical science students and other at-risk groups, as well as the population of the at-risk territories selected in stages.
9,618,831 were administered dose during the health intervention.
Intervention study
As part of the research associated with the Cuban candidate vaccines Soberana 02 and Abdala, an intervention study in at-risk groups was conducted, targeting subjects in at-risk groups and which could provide relevant data, which began in March 2021.
BioCubaFarma health workers and other risk groups participated in the provinces of Havana, Santiago de Cuba, Granma and Guantánamo, with 454,064 doses administered.
clinical tests
The development of clinical trials with Cuban candidate vaccines Soberana 02, Abdala and Soberana Plus (for convalescents) has been approved by Cecmed and implemented in volunteers from selected territories.
From March 2021, volunteers selected by researchers from Havana, Santiago, Granma and Guantánamo participated.
266,466 doses were administered (Placebos administered during clinical trials are excluded from this figure).
